Partner

Ilseok KANG

Primary Industry Experience :
  • Biotechnology / Life Sciences
  • Specialized
    Practice Areas :
    Patent Prosecution, Litigation and Enforcement Activities, Counseling and Legal Opinions, Technology Transfer / Licensing

    Biography

    Ilseok Alban Kang is a partner in the Chemical/Pharmaceutical/Life Sciences Group and leads the firm’s China Practice Division. He provides his clients with a comprehensive understanding of Chinese and Korean patent law, along with close to twenty years of domestic and international practice experience.

    Mr. Kang’s law practice encompasses all facets of patent prosecution, enforcement, and patent portfolio analysis in fields including biotechnology, pharmaceuticals, polymers, textiles, fuel oils, semiconductor materials, metal coating, and secondary batteries. He leads teams before the Board of Trials with his expert analysis and breakdown of technology and precedents to bring about the best result for the firm’s clients.

    Having spent three years earning his law degree from Peking University, Mr. Kang helps bridge the Chinese and Korean patent systems, serving as a frequent lecturer in conferences sponsored by the International Intellectual Property Training Institute and the Korea Intellectual Property Association regarding the IP system in China. He is also frequently invited to participate in conferences sponsored by the China National Intellectual Property Administration to provide updates and lectures on current IP matters in Korea, as well as providing expert insight and interpretation services for events co-sponsored by the Korean and Chinese patent offices.

    Profile

    • Bar Admissions
      • ·Korean Patent Bar (2004)
    • Education
      • ·Peking University Law School (Juris Master, 2014)
      • · Beijing Language and Culture University, College of Intensive Chinese Training (Course completion, 2010)
      • · Seoul National University, Department of Molecular Biology (B.S., 1997)
    • Experience
      • ·FirstLaw P.C. (2005~present)
      • · Lee & Lee International Patent & Law Office (2004-2005)
    • Professional Activities
      • ·Korea Patent Attorneys Association (KPAA)
    • Languages
      • ·Korean, English, Chinese and Japanese

    INSIGHT

    FirstLaw Newsletter

    SEPARATE PRODUCTION/SALE OF MULTIPLE COMPONENTS HELD NOT TO INFRINGE PATENT DIRECTED TO VACCINE COMPOSITION THEREOF

    June 30, 2025.

    FirstLaw Newsletter

    PATENTABILITY CRITERIA FOR CRYSTALLINE FORM INVENTIONS FURTHER DELINEATED

    June 28, 2024.

    FirstLaw Newsletter

    PRODUCT DESIGNER'S INTENT HELD IRRELEVANT IN DETERMINING PATENT INFRINGEMENT

    March 31, 2020.